---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-000437"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2026-01-06T23:59:59+00:00"
generated_at: "2026-05-16T11:32:19.894407+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Genprex reports positive preclinical GPX-002 data in T2D; first NHP achieved normal glucose tolerance at 7 months

## Summary
- First T2D NHP received intraductal AAV infusion of GPX-002 (Pdx1+MafA) and showed normal glucose tolerance test at 7 months.
- Second NHP via direct pancreas injection improved glucose tolerance at 3 months but did not reach normal levels.
- T2D mice treated with GPX-002 showed reversal of hyperglycemia and normal glucose levels at 4 weeks post-surgery.
- GPX-002 aims to rejuvenate exhausted beta cells; company says data supports potential to address 90-95% of diabetes patients (T2D).
- Preclinical studies continuing; formal toxicology and IND submission planned.

## SEC filing metadata
- accession: 0001437749-26-000437
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2026-01-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774926000437/0001437749-26-000437-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774926000437/gnpx20251201_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-000437
- JSON: https://secwatch.observer/filing/0001437749-26-000437.json
- Plain text: https://secwatch.observer/filing/0001437749-26-000437.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.